Last reviewed · How we verify
Pharmacological conventional treatment
This is a conventional pharmacological treatment approach rather than a specific drug entity.
At a glance
| Generic name | Pharmacological conventional treatment |
|---|---|
| Also known as | Conventional treatment |
| Sponsor | Psicofarma, S.A. De C.V. |
| Modality | Small molecule |
| Phase | Phase 3 |
Mechanism of action
The term 'Pharmacological conventional treatment' refers to standard-of-care therapeutic interventions using established pharmaceutical agents, rather than a novel or investigational drug. Without specification of the therapeutic area or condition, the exact mechanism cannot be determined. Psicofarma, S.A. De C.V. is a Mexican pharmaceutical company, but the specific drug name and mechanism are not provided.
Approved indications
Common side effects
Key clinical trials
- Brentuximab Vedotin and Combination Chemotherapy in Treating Children and Young Adults With Stage IIB, Stage IIIB, IVA, or IVB Hodgkin Lymphoma (PHASE3)
- Erdafitinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With FGFR Mutations (A Pediatric MATCH Treatment Trial) (PHASE2)
- Trametinib With or Without Whole Brain Radiation Therapy in Treating Patients With Brain Metastases (PHASE1)
- Ensartinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With ALK or ROS1 Genomic Alterations (A Pediatric MATCH Treatment Trial) (PHASE2)
- A Study to Investigate the Effect of 0.003% AR-15512 on Subjects With Dry Eye Disease (PHASE3)
- Pharmacological Comparison of Continuous and Intermittent Infusions of Cloxacillin (NA)
- Clinical Trial to Evaluate the Efficacy and Safety of the Aurora® Digital Medical Device in Adult Patients With Moderate to Severe Generalized Anxiety Disorder (PHASE3)
- A Study to Evaluate 0.003% AR-15512 Safety and Drop Attributes (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: